Evidence map›Paper›PMID 37152255›Full record

ArticleChemical science2023

Development of fluorogenic substrates for colorectal tumor-related neuropeptidases for activity-based diagnosis.

Norimichi Nagano, Yuki Ichihashi, Toru Komatsu, Hiroyuki Matsuzaki, Keisuke Hata, Toshiaki Watanabe, Yoshihiro Misawa, Misa Suzuki, Shingo Sakamoto, Yu Kagami and 7 more

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Norimichi NaganoGraduate School of Pharmaceutical Sciences, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan komatsu@g.ecc.u-tokyo.ac.jp uranokun@m.u-tokyo.ac.jp.ORCID https://orcid.org/0000-0003-0214-8546
Yuki IchihashiGraduate School of Pharmaceutical Sciences, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan komatsu@g.ecc.u-tokyo.ac.jp uranokun@m.u-tokyo.ac.jp.
Toru KomatsuGraduate School of Pharmaceutical Sciences, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan komatsu@g.ecc.u-tokyo.ac.jp uranokun@m.u-tokyo.ac.jp.
Hiroyuki MatsuzakiDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan.
Keisuke HataDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan.
Toshiaki WatanabeDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan.
Yoshihiro MisawaGraduate School of Pharmaceutical Sciences, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan komatsu@g.ecc.u-tokyo.ac.jp uranokun@m.u-tokyo.ac.jp.
Misa SuzukiGraduate School of Pharmaceutical Sciences, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan komatsu@g.ecc.u-tokyo.ac.jp uranokun@m.u-tokyo.ac.jp.
Shingo SakamotoGraduate School of Pharmaceutical Sciences, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan komatsu@g.ecc.u-tokyo.ac.jp uranokun@m.u-tokyo.ac.jp.
Yu KagamiGraduate School of Pharmaceutical Sciences, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan komatsu@g.ecc.u-tokyo.ac.jp uranokun@m.u-tokyo.ac.jp.
Ayumi KashiroInstitute for Advanced Medical Sciences, Nippon Medical School 1-1-5 Sendagi Bunkyo-ku Tokyo 113-0033 Japan.
Keiko TakeuchiInstitute for Advanced Medical Sciences, Nippon Medical School 1-1-5 Sendagi Bunkyo-ku Tokyo 113-0033 Japan.
Yukihide KanemitsuNational Cancer Center Hospital 5-1-1 Tsukiji Chuo-ku Tokyo 104-0045 Japan.
Hiroki OchiaiNational Cancer Center Hospital 5-1-1 Tsukiji Chuo-ku Tokyo 104-0045 Japan.
Rikiya WatanabeCluster for Pioneering Research, RIKEN 2-1 Hirosawa Wako Saitama 351-0198 Japan.ORCID https://orcid.org/0000-0001-7146-2745
Kazufumi HondaInstitute for Advanced Medical Sciences, Nippon Medical School 1-1-5 Sendagi Bunkyo-ku Tokyo 113-0033 Japan.
Yasuteru UranoGraduate School of Pharmaceutical Sciences, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033 Japan komatsu@g.ecc.u-tokyo.ac.jp uranokun@m.u-tokyo.ac.jp.
The University of Tokyo · JPNippon Medical School · JPRIKEN · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The M3 metalloproteases, neurolysin and THOP1, are neuropeptidases that are expressed in various tissues and metabolize neuropeptides, such as neurotensin. The biological roles of these enzymes are not well characterized, partially because the chemical tools to analyse their activities are not well developed. Here, we developed a fluorogenic substrate probe for neurolysin and thimet oligopeptidase 1 (THOP1), which enabled the analysis of enzymatic activity changes in tissue and plasma samples. In particular, the probe was useful for studying enzyme activities in a single-molecule enzyme assay platform, which can detect enzyme activity with high sensitivity. We detected the activity of neurolysin in plasma samples and revealed higher enzyme activity in the blood samples of patients with colorectal tumor. The result indicated that single-molecule neurolysin activity is a promising candidate for a blood biomarker for colorectal cancer diagnosis.

Identifiers

PMID37152255
PMCPMC10155908
OpenAlexW4365131818

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.